Target detail
ACTR3
actin related protein 3
Data: Live structured evidence (Supabase)
Foundation row from public.targets — full Open Targets / ChEMBL preload remains a future operator job (Phase 8H+).
Display name: actin related protein 3
Aliases: ACTR3, actin related protein 3
Type / organism: protein_coding · Homo sapiens
Source: opentargets · ENSG00000115091
Index freshness: last_synced_at 2026-05-15T18:28:38.362+00:00 · updated 2026-05-15T18:28:38.813144+00:00
Limitations & build flags
- Read-only structured navigator
- No clinical outcome benefit inferred
- Trial presence does not imply success
- Drug identity may require normalization
- Terminated/withdrawn trials must remain visible
This symbol is listed in public.targets (operator seed or future preload). Connector-backed sections below may still show empty states until ChEMBL / Open Targets / ClinicalTrials.gov mirror rows exist for this marker.
Connectors represented in loaded rows for ACTR3. Empty groups mean no matching rows — not a claim about biology or clinical use.
- Open TargetsLive when indexed
Disease–target evidence rows when operators run enrich:opentargets (GraphQL from trusted scripts only).
- ChEMBLLive when indexed
Drug–target and related enrichment rows when operators run enrich:chembl (server/CLI only).
- CANTI signal builderLive when indexed
Deterministic repurposing-signal rows produced by the in-repo signal builder when operators run the build pipeline.
Rows from disease_target_evidence for this symbol.
glioblastoma
literature · opentargets
Drug records tied via drug_targets — mechanistic linkage only.
Y-39983
chembl571948
TAK-733
chembl1615025
PELITINIB
chembl607707
OSI-027
chembl3120215
TUCATINIB
chembl3989868
SNS-314
chembl482767
VX-702
chembl1090090
AMG-208
chembl496102
TOVORAFENIB
chembl3348923
PAZOPANIB
chembl477772
ENCORAFENIB
chembl3301612
REGORAFENIB
chembl1946170
AMUVATINIB
chembl2103851
SORAFENIB
chembl1336
ULIXERTINIB
chembl3590106
CHEMBL4129274
chembl4129274
BMS-754807
chembl575448
RABUSERTIB
chembl3039517
VANDETANIB
chembl24828
CRIZOTINIB
chembl601719
TIRBANIBULIN
chembl571546
PACRITINIB
chembl2035187
FGFR INHIBITOR DEBIO 1347
chembl3907479
GALUNISERTIB
chembl2364611
AZD-6482
chembl2165191
ENZASTAURIN
chembl300138
AFATINIB
chembl1173655
COBIMETINIB
chembl2146883
XL-019
chembl3545328
AZD-4547
chembl3184679
MK-5108
chembl3600873
AZD-8186
chembl3408248
HMN-214
chembl3991927
TAK-593
chembl2180604
TIVOZANIB
chembl1289494
FOSTAMATINIB
chembl2103830
FEDRATINIB
chembl1287853
AZD-5438
chembl488436
PONATINIB
chembl1171837
VEMURAFENIB
chembl1229517
GOLVATINIB
chembl3039525
CYC-116
chembl482967
BUPARLISIB
chembl2017974
DANUSERTIB
chembl402548
SARACATINIB
chembl217092
MK-2206
chembl1079175
BGT-226 FREE BASE
chembl3218578
LESTAURTINIB
chembl603469
AMG-900
chembl2140408
BOSUTINIB
chembl288441
PICTILISIB
chembl521851
CHEMBL2030402
chembl2030402
NILOTINIB
chembl255863
MOTESANIB
chembl572881
TELATINIB
chembl2079588
DECERNOTINIB
chembl3039513
ENMD-2076
chembl482968
OSI-632
chembl253969
CHEMBL5653589
chembl5653589
AV-412 FREE BASE
chembl2138625
CHEMBL4084193
chembl4084193
CHEMBL3991934
chembl3991934
ROCILETINIB
chembl3545308
PALBOCICLIB
chembl189963
RUBOXISTAURIN
chembl91829
GSK-461364
chembl1908394
TG100-801
chembl403989
SAR-407899 FREE BASE
chembl1667969
OSIMERTINIB
chembl3353410
CHEMBL3688339
chembl3688339
CHEMBL3218575
chembl3218575
TEMSIROLIMUS
chembl1201182
LINIFANIB
chembl223360
CHEMBL400402
chembl400402
PF-04691502
chembl1234354
SILMITASERTIB
chembl1230165
SU-014813
chembl1721885
LENVATINIB
chembl1289601
IDELALISIB
chembl2216870
CHEMBL3991935
chembl3991935
BRIVANIB
chembl377300
KW-2449
chembl1908397
ENTRECTINIB
chembl1983268
CUDC-101
chembl598797
PF-03814735
chembl4289017
SONOLISIB
chembl411907
SELUMETINIB
chembl1614701
MK-2461
chembl1822792
DEFACTINIB
chembl3137331
AC-480
chembl1645462
CERITINIB
chembl2403108
CHEMBL2376648
chembl2376648
NMS-1286937
chembl1094408
AFURESERTIB
chembl2219422
RGB-286638
chembl3545083
MERESTINIB
chembl3545307
BI-2536
chembl513909
AT-7519
chembl445813
AZD-8055
chembl1801204
MIDOSTAURIN
chembl608533
SGI-1776
chembl1952329
UCN-01
chembl574737
CC-401
chembl1614713
TANZISERTIB
chembl1950289
RO-4987655
chembl1614766
NINTEDANIB
chembl502835
GSK-1070916
chembl1090479
TAK-285
chembl1614725
SUNITINIB
chembl535
LINSITINIB
chembl1091644
AT-9283
chembl495727
MUBRITINIB
chembl1614707
PERIFOSINE
chembl372764
PF-03758309
chembl3128043
IBRUTINIB
chembl1873475
IMD-0354
chembl536151
PIMASERTIB
chembl2107832
RAF-265
chembl558752
MK-8033
chembl2323775
DASATINIB
chembl5416410
DEFOSBARASERTIB
chembl215152
LUCITANIB
chembl2220486
CHEMBL3991933
chembl3991933
TAK-901
chembl3544932
CP-724714
chembl483321
CHEMBL2048872
chembl2048872
MIRDAMETINIB
chembl507361
ALVOCIDIB
chembl428690
BINIMETINIB
chembl3187723
AEE-788
chembl587723
MLN-8054
chembl259084
BARICITINIB
chembl2105759
BMS-911543
chembl3545215
SOTRASTAURIN
chembl565612
BMS-387032
chembl296468
PHA-793887
chembl1230607
GLESATINIB
chembl3989914
AT-13148
chembl3544960
AZD-8330
chembl3182621
ICOTINIB
chembl2087361
ERLOTINIB
chembl553
DACOMITINIB ANHYDROUS
chembl2110732
CABOZANTINIB
chembl2105717
CAPMATINIB
chembl3188267
K-252A
chembl281948
GSK-1059615
chembl3544966
ALPELISIB
chembl2396661
UPROSERTIB
chembl3137336
GILTERITINIB
chembl3301622
DABRAFENIB
chembl2028663
CEDIRANIB
chembl491473
GSK-690693
chembl494089
QUIZARTINIB
chembl576982
WHI-P131
chembl405130
ALECTINIB
chembl1738797
TEPOTINIB
chembl3402762
TRAMETINIB
chembl2103875
TIDEGLUSIB
chembl3545157
VOXTALISIB
chembl3545366
PEXMETINIB
chembl3991932
CRENOLANIB
chembl2105728
RAVOXERTINIB
chembl3544964
AZD-7762
chembl2041933
DOVITINIB
chembl522892
AZD-1480
chembl1231124
R-406
chembl475251
AXL-1717
chembl283120
COPANLISIB
chembl3218576
REBASTINIB
chembl1738757
RIDAFOROLIMUS
chembl2103839
RIGOSERTIB
chembl1241855
LAPATINIB
chembl554
MOMELOTINIB
chembl1078178
PF-00562271
chembl1084546
EVEROLIMUS
chembl1908360
DACTOLISIB
chembl1879463
Cerdulatinib Hydrochloride
chembl3991929
GEDATOLISIB
chembl592445
ORANTINIB
chembl274654
VATALANIB
chembl101253
HYDROXYFASUDIL
chembl1233300
BARASERTIB
chembl415049
APITOLISIB
chembl1922094
AEW-541
chembl551064
SCH-900776
chembl2386889
CHEMBL3699142
chembl3699142
PEXIDARTINIB
chembl3813873
LOSMAPIMOD
chembl1088752
FILGOTINIB
chembl3301607
RIVOCERANIB
chembl3186534
CANERTINIB
chembl31965
TANDUTINIB
chembl124660
GEFITINIB
chembl939
DINACICLIB
chembl2103840
TESEVATINIB
chembl3544983
JNJ-38877605
chembl2133806
TIVANTINIB
chembl2103882
TOFACITINIB
chembl221959
ADAVOSERTIB
chembl1976040
XL-228
chembl3545085
disease_drug_evidence rows on linked drugs whose evidence_type suggests approved-elsewhere discussion context.
No matching rows
Import repoDB-compatible disease–drug evidence or add structured rows to surface discussion candidates here.
Mirror rows whose text fields mention this symbol — registry context only.
No matching live evidence found
Populate clinical_trials via the registry enrichment flow; this panel matches the symbol token in titles, conditions, or interventions.
Repurposing signal rows for drugs linked to this target via drug_targets.
Repurposing research signal · BOSUTINIB · v0.1
Deterministic research signal for BOSUTINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · AT-9283 · v0.1
Deterministic research signal for AT-9283. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · ALVOCIDIB · v0.1
Deterministic research signal for ALVOCIDIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · BMS-387032 · v0.1
Deterministic research signal for BMS-387032. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · CANERTINIB · v0.1
Deterministic research signal for CANERTINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · CEP-32496 · v0.1
Deterministic research signal for CEP-32496. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · BAFETINIB · v0.1
Deterministic research signal for BAFETINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubStructured rows with negative evidence_direction on disease–drug or signal tables.
No negative-direction rows
When structured evidence includes explicit negative direction fields, they surface here for oncology review.
No ClinicalTrials.gov mirror rows mention this symbol in titles, conditions, or interventions (within the loaded window).
- chembl: 238
- canti_signal_builder: 7
- opentargets: 1
Structured evidence rows link this marker to cohort contexts when ingested — interpret as research context only.
Disease contexts
0
Linked drugs
0
Linked in dataset
0
Research signals
0
Doctor-discussion candidate and related tags are descriptive only.
Signals list: Live structured evidence (Supabase)
Repurposing research signal · ALVOCIDIB · v0.1
Deterministic research signal for ALVOCIDIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · CEP-32496 · v0.1
Deterministic research signal for CEP-32496. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · CANERTINIB · v0.1
Deterministic research signal for CANERTINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · BOSUTINIB · v0.1
Deterministic research signal for BOSUTINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · BMS-387032 · v0.1
Deterministic research signal for BMS-387032. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · AT-9283 · v0.1
Deterministic research signal for AT-9283. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · BAFETINIB · v0.1
Deterministic research signal for BAFETINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hub